Adalta Limited (ASX:1AD)

Sam Cobb
Market Cap (AUD): 18.03M
Sector: Health Care
Last Trade (AUD): 0.11 +0.01 (+4.76%)
Tab Bar

1. About

AdAlta Limited is a drug discovery and development company focused on using its powerful technology platform to generate a promising new class of protein therapeutics, known as i-bodies, for treating a wide range of human diseases.

i-bodies are a human analogue of the antigen binding domain of the shark antibody; they combine the high target specificity and affinity advantages of antibodies with the beneficial features of small molecule drugs.

The Company’s lead i-body candidate, AD-114, is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need. AdAlta intends to continue further discovery and development activities directed towards other disease targets for in-house development or partnering.

The Company is led by an experienced management team and Board and is supported by a world class scientific advisory board.

Both AdAlta’s i-body technology platform and lead i-body drug candidate, AD-114, are protected by a strong portfolio of worldwide granted patents and pending applications.

AdAlta is headquartered in Melbourne, Australia.

2. Business model

3. Strategy

4. Markets

5. Competition

6. History

7. Team

8. Financials

9. Risk